诺和诺德：欧盟委员会批准更高效剂量的Wegovy®注射液用于成人肥胖症治疗

Core Viewpoint - The European Commission has approved a new weekly maintenance dose of 7.2 mg for Wegovy® (semaglutide injection) for adult obesity patients, allowing for greater weight loss while maintaining muscle function [1] Group 1: Regulatory Approvals - The approval allows EU doctors to prescribe the 7.2 mg dose, which involves a single injection of three 2.4 mg doses, still administered weekly [1] - A marketing authorization application for a single-dose 7.2 mg injection pen has been submitted to the EU, with potential approval expected this year [1] - Wegovy® 7.2 mg has already been approved and launched in the UK, while the FDA and other regulatory bodies in various countries are reviewing its registration applications [1] Group 2: Patient Treatment Options - Adult obesity patients in the EU can increase their dosage to 7.2 mg after using Wegovy® 2.4 mg for at least four weeks to achieve more significant weight loss [1]